Arctic Aurora LifeScience A NOK

Equity fund

1 year

Region

USA

Largest region

Medium

Risk

Cost

Morningstar

 

Partial 

Sustainability

Development

Last 5 years
( ann.)

Description

  • Fondets målsetting er å øke verdien av andelseiernes investering gjennom å investere i aksjer globalt innenfor sektorer som farmasi, bioteknologi o.l.

Investment horizon

  • Arctic Aurora LifeScience A NOK is a Equity fund. This mutual fund type is suitable for those who plan to save for at least 6 years.

Characteristics

  • Minimum amount
  • Sharpe 3 years
  • Price/NAV

    04 Jun 2025

  • Start date
    27 Nov 2016
  • ISIN
    IE00BYQ7ZL84

Risk

  • Medium (4 of 7)

Morningstar rating

  • The Morningstar Rating is an objective standard that tells us how well a fund has done compared to similar funds. If a fund performs better than other funds it is compared with, it receives a high rating. Correspondingly, a fund receives a low rating if it performs worse than similar funds.

Sustainability

Costs

  • Ongoing costs

    Includes management fees of 2,00 %

  • Platform fee
  • Kickback fee
  • Annual running costs
  • Performance-based fee
  • Any transaction costs to the manager are not included in the cost overview. These are stated under cost details on the summary page before you purchase the fund. Costs for any currency exchanges are not included.

Allocation

  • Stocks 97%
    Interest 3%

Portfolio

Shows the fund's largest investments.

  • Eli Lilly and Co
    7.0%
  • AstraZeneca PLC
    5.9%
  • Novartis AG Registered Shares
    4.0%
  • argenx SE
    3.3%
  • Sanofi SA
    3.1%
  • Daiichi Sankyo Co Ltd ADR
    2.7%
  • Alltrna, Inc -Series B Preferred Stock
    2.7%
  • McKesson Corp
    2.0%
  • Boston Scientific Corp
    2.0%
  • Johnson & Johnson
    2.0%